Aortic aneurysm occurs when the wall of the body's largest artery, the aorta, weakens and swells.
The disease progresses slowly and affects some five per cent of men and one per cent of women over the age of 60.
The condition is largely symptom-free and is normally not discovered until late in its development when it threatens to rupture and cause life-threatening haemorrhaging.
There are currently no drugs for preventing and treating aortic aneurysm.
"Our results are exciting and open the way for a medical treatment of this serious vascular disease," said Professor Jesper Z Haeggstrom from Karolinska Institutet.
In earlier studies, the research group found high levels of particular inflammatory signal substances called leukotrienes in the vascular walls of patients operated on for aortic aneurysm.
Leukotrienes drive inflammation and are known for their potential to cause asthma. Since the asthma drug montelukast blocks leukotrienes, the team decided to examine whether it could also have an effect on aortic aneurysm.
"This study is particularly interesting from a therapeutic perspective since montelukast is a safe drug with very few side-effects, which means it can be taken over a long period of time," said Haeggstrom.
"In the study we used drug doses equivalent to those used in the treatment of asthma patients," he said.
The researchers hope to be able to start a controlled clinical trial to test the drug's efficacy on patients with aortic aneurysm.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
